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Sickle cell anemia (SCA) is a genetic disorder characterized
by homozygous hemoglobin S (Hb S), chronic hemolytic ane-
mia  and painful episodes.1 Patients with SCA usually require
red blood cell (RBC) transfusions to manage complications
and to reduce morbidity during surgical procedures.1 One
possible complication of multiple transfusions is alloimmu-
nization, which occurs due to the recognition of foreign
surface antigens on transfused RBC by antibodies produced
by the recipient (alloantibodies).2,3 This phenomenon can lead
to a delayed hemolytic transfusion reaction/hyperhemolysis
syndrome (DHTR/HS).1 However, patients who present this
syndrome generally do not show any new alloantibodies, and
a direct antiglobulin test (DAT) is usually negative.4,5 As no
new antibodies are detected and the symptoms can be con-
fused with other SCA complications, this syndrome represents
an important diagnostic challenge. The recognition of this
syndrome is important for the management of the symp-
toms and to prevent future onsets. As it is triggered by blood
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reserved.transfusions, it is important to recognize it and avoid further
transfusions.
This paper aims to highlight the importance of recogniz-
ing HS, because wrong management of a crisis with an extra
RBC transfusion can increase the hemolysis and cause life-
threatening anemia. We report a case of a young girl with SCA
that developed an episode of hyperhemolysis seven days after
a blood transfusion.
Case  report
An 18-year-old girl with SCA was admitted with acute chest
syndrome and was treated with intravenous ﬂuid, analge-
sia and antibiotics. Her blood tests showed an hemoglobin
(Hb) level of 6.10 g/dL, hematocrit (Ht) of 19.2%, lactate dehy-
drogenase (LDH) of 743 U/L, and bilirubin level of 5.95 mg/dL
(unconjugated: 3.69 mg/dL). She received one unit of pheno-
typically matched packed RBCs, with no complications during, Brazil.
the procedure. Laboratorial exams at discharge showed Hb
level of 9.32 g/dL, Ht of 30.8%, LDH of 643 U/L and bilirubin level
of 4.29 mg/dL.
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Two days after discharge (seven days after the RBC trans-
usion) she was re-admitted with jaundice, hemoglobinuria,
ain crisis, paresthesia of feet, lethargy, dyspnea and pul-
onary rales in lower third of both lungs. Her Hb level
as 4.71 g/dL, Ht 14.7%, white blood cell count (WBC)
7.8 × 109 cells/L, LDH 3910 U/L and bilirubin 13.65 mg/dL
unconjugated 9.55 mg/dL). No RBC antibodies were detected
sing the gel method (Serascan Diana 2/Serascan Diana 2P –
rifols, S.A.) and conﬁrmed with the ID-System (BIO RAD®).
LA antibodies were also not detected by a LABScreen® MULTI
One Lambda Inc.) assay. Her Hb A level was 4% and Hb S
as 86%. Excluding infection and other SCD complications,
e considered the hypothesis of DHTR/HS and started high-
ose intravenous methylprednisolone (1.5 g/day). One day
fter, her Hb levels dropped even further, reaching 3.0 mg/dL
nd her LDH levels increased to 6680 U/L, accompanied by a
ecreased level of consciousness. Given the severity of the
ase we decided to give her one unit of packed RBCs. We also
tarted the administration of 1 g/kg intravenous immunoglob-
lin (IVIG), erythropoietin (4000 U) and folic acid. She improved
nd was discharged after two weeks with Hb of 7.96 mg/dL,
t of 24.5%, LDH of 1694 U/L and bilirubin level of 5.69 mg/dL.
erial immunohematological studies performed after this cri-
is also showed negative DAT and HLA antibodies.
iscussion
 young SCA patient was diagnosed with DHTR/HS seven days
fter a RBC transfusion. She presented with severe anemia, Hb
evels lower than before the transfusion, signs of hemolysis
nd pain crisis. Faced with this situation and excluding other
auses, the hypothesis of DHTR/HS was established. DHTR/HS
s an uncommon but severe complication of alloimmuniza-
ion that occurs in patients submitted to RBC transfusions,
specially those with SCD, who are submitted to multiple
ransfusions during their lives.4 The rate of alloimmuniza-
ion in SCD patients is around 5–36%,1,6 and the incidence of
HTR/HS in SCD patients is around 1–19%.1,7
When we evaluated her medical chart, we observed that
he had a similar condition three years previously. Two
ays before a hip surgery she underwent a partial exchange
ransfusion and received phenotypically matched RBCs.
efore transfusion her Hb level was 7.2 mg/dL, Ht was 21.9%
nd WBC  was 17.3 × 109 cells/L. The surgery went well, and
he did not need any other transfusions during or after the
rocedure. However, ﬁve days after the surgery (seven days
fter the transfusion) she was admitted as an emergency
resenting with fatigue, jaundice, pallor and tachycardia. She
id not exhibit fever or pain. Her laboratory tests showed Hb
f 4.08 mg/dL, Ht of 12.7%, WBC  of 41.5 × 109 cells/L, LDH of
346 U/L and bilirubin level at 12.09 mg/dL. Concerned about
he risk of infection, intravenous ﬂuid and oxacillin were
dministered. Blood cultures were negative. She was also
anaged with the transfusion of one unit of packed RBCs. Her
ymptoms improved and two days after she was discharged
n oral antibiotics. On that occasion she was diagnosed
ith infection, despite the fact that she did not present
ith fever or signs of bacterial infection. The symptoms of
HTR/HS can easily be mistaken for other sickle cell disease 1 5;3  7(4):266–268 267
complications, including infections and vaso-occlusive
crises.7 The most important issue is to recognize the tem-
poral appearance of the symptoms and its correlation with
transfusions of RBCs. DHRT/HS usually begins seven days
after a RBC transfusion (range: 4–11 days).1 It is also important
to measure the Hb levels. Thus, the diagnosis of DHRT/HS is
made by clinical features, time between RBC transfusion and
clinical onset, laboratory tests and exclusion of differential
diagnoses.6
Before the ﬁrst supposed episode, when she was 15 years
old, our patient had received over 16 RBC transfusions.
Thus, she had a high risk of developing alloantibodies, even
receiving phenotypically matched RBCs. Over time, some
alloantibodies decrease to levels not detected by serological
tests.1 Once those antibodies are not detected, cells seem to
be phenotypically compatible and are released for transfu-
sion. However, subsequent re-exposure to the antigens that
triggered the antibody production stimulates an anamnestic
response leading to hemolysis.1,6
HS is mainly caused by destruction of both donor and
recipient RBCs, but the exact mechanism is still not well
understood.4,5 One possible explanation for autologous RBC
destruction is “bystander hemolysis” whereby sickled RBCs
are destroyed by antibodies without expressing the speciﬁc
antigen against which this antibody is directed.5 Another
explanation for the patient’s RBC reduction is the activa-
tion of macrophages leading to peripheral destruction. Sickled
RBCs expose some antigens (e.g. phosphatidylserine) and high
levels of IgG on their outer surface, allowing recognition by
hyperactivated macrophages.6 Our patient did not exhibit any
alloantibodies or HLA antibodies after the hemolysis crisis,
so it is believed that the patient’s and donor’s RBCs were
destroyed by the hyperactivated macrophages.
HS is characterized by severe anemia, with Hb lower
than pre-transfusional levels, pain, fever and signs of
hemolysis (jaundice, increased LDH, hyperbilirubinemia and
hemoglobinuria).1,5 Reticulocytopenia may be present5; HS
can be classiﬁed into acute or delayed.4 In the ﬁrst situa-
tion, symptoms appear within seven days of receiving RBCs,
and a DAT is generally negative. The delayed form usually
appears seven days after a transfusion.4 DAT results are usu-
ally positive and new alloantibodies can be detected in the
patient’s serum.5 DHTR/HS can also be associated to some
complications such as acute chest syndrome, congestive heart
failure, pancreatitis, acute renal failure, subarachnoid hemor-
rhage, acute respiratory distress syndrome, pneumonia, and
splenic sequestration.1,3 There is no speciﬁc test to diagnose
DHTR/HS, and in many  cases no alloantibodies are detected.
Win5 proposes that laboratory investigations when DHTR/HS
is suspected should contemplate reticulocyte count, serum
bilirubin level, LDH, DAT, screening for antibodies, serial mea-
surement of RBCs, Hb electrophoresis, and high-performance
liquid chromatography (HPLC) analysis of the urine.
The treatment of DHRT/HS is based on the exclu-
sion of other causes and management of steroids and
immunoglobulins.4,5,8 Mild cases can receive prednisolone
(1–2 mg/kg/day) with close monitoring of Hb levels.5 Avoiding
new RBC transfusions is an important issue to prevent worsen-
ing of symptoms, but in some cases the Hb decreases to levels
so low that RBC transfusions become necessary. Our patient
oter.
r
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reached a very low Hb level with a decreased level of con-
sciousness. We  compared risks and beneﬁts and decided to
give her one unit of RBCs, aware that subsequent transfusions
could exacerbate hemolysis and become life threatening.4 We
initiated IGIV at the same time to avoid exacerbation of the
hemolysis.5 We  also treated her with methylprednisolone,
erythropoietin and folic acid. Steroids and IVIG may have a
synergistic effect in suppressing macrophages,4,5 and new evi-
dence suggests that they can shorten the course of hemolysis.5
The role of erythropoietin is not well established, but its serum
levels are low for this level of anemia.5 Win suggests that
erythropoietin may correct anemia in DHTR/HS by directly
stimulating erythroid precursors and preventing the destruc-
tion of young RBC.5
Other studies have reported a similar scenario, success-
fully treating patients with life-threatening HS with RBC
transfusions, steroids and immunoglobulin.4,6,9 One study5
recommends the use of low-dose IVIG (0.4 g/kg/day) for ﬁve
days and intravenous methylprednisolone (0.5 g/day for adults
and 4.0 mg/kg/day for children) for two days. Some studies also
suggest the use of Rituximab and cyclophosphamide in severe
cases.10
HS is a severe disease and few recurrent cases have been
described in the literature. In some cases it can be life threat-
ening. This condition can be misdiagnosed with other SCD
complications, so it is very important to think about DHTR/HS
when faced with a hemolysis crisis in a SCD patient, espe-
cially after a RBC transfusion. The correct management of
HS by avoiding further transfusions and giving steroids and
immunoglobulin can change the course of the disease.Conﬂicts  of  interest
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